FREMONT, Calif., July 18 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that it will release its financial results for the second quarter of 2007 following the close of the U.S. financial markets on Wednesday, August 1, 2007. PDL will hold a conference call at 4:30 p.m. Eastern time on August 1, 2007 to discuss the company’s performance during the second quarter and first half of 2007, and provide an update on progress towards its full-year 2007 objectives.
A webcast of the conference call will be available through the PDL website: http://www.pdl.com. Please connect to this website at least 15 minutes prior to the webcast to allow time for any software download that may be needed to hear the webcast. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A replay will be available at www.pdl.com starting approximately one hour after completion of the webcast.
An audio replay will also be available by telephone from approximately 6:30 p.m. Eastern time on August 1, 2007 through 6:30 p.m. Eastern time on September 1, 2007. To access the replay, dial 800-642-1687 from inside the U.S. or 706-645-9291 from outside the U.S. and enter conference ID number 6350281, when prompted.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of commercial products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL’s research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit http://www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL BioPharma, Inc.
PDL BioPharma, Inc.
CONTACT: Ami Knoefler, Corporate and Investor Relations, +1-510-284-8851,ami.knoefler@pdl.com, or Jean Suzuki, Investor Relations, +1-510-574-1550,jean.suzuki@pdl.com, both of PDL BioPharma, Inc.
Web site: http://www.pdl.com//
